Fluid Therapy: Clinical Trials

21 trials of Fluid Therapy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 completed, 3 active not recruiting, 2 recruiting, 2 unknown. 21 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 321Completed 12, Active not recruiting 3, Recruiting 2, Unknown 2, Not yet recruiting 1, Terminated 1
Phase 21Recruiting 1

Follow Fluid Therapy: new trials by email Literature Review of Fluid Therapy trials Research Report on Fluid Therapy

Trials (filtered) newest first · largest first

All 21 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
SGB for Prevention of Postop A-Fib After Cardiac SurgeryTrial
Stellate Ganglion Block Injection with 10 mL 0.5% Bupivacaine, Stellate Ganglion Block Injection with 10 mL Normal Saline - Atrial Fibrillation, Postoperative Atrial Fibrillation
Phase 3Not yet recruitingThe Cleveland Clinic602026-10-152026-10-27
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
IgPro20 - Secondary Immune Deficiency
Phase 3RecruitingCSL Behring632026-09-152026-10-14
Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial
Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy - Multiple Myeloma
Phase 3CompletedNational Cancer Institute (NCI)12022-02-162025-05-23
Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis
Vasopressor, Fluids - Shock, Septic
Phase 3Active not recruitingAustralian and New Zealand Intensive Care Research Centre10002021-10-262026-11-09
A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A
PXT3003, PXT3003 placebo - Charcot-Marie-Tooth Type 1A
Phase 3CompletedTasly GeneNet Pharmaceuticals Co., Ltd1762021-09-282025-01-09
Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants
Vigabatrin, Rapamycin, Placebo - Tuberous Sclerosis Complex
Phase 2 / Phase 3RecruitingKatarzyna Kotulska602021-05-072026-10-22
Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency
GC5107 - Primary Immune Deficiency
Phase 3Active not recruitingGC Biopharma Corp242020-12-212025-07-25
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspirate - Mantle Cell Lymphoma
Phase 3Active not recruitingECOG-ACRIN Cancer Research Group6892017-11-272026-09-14
Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID
IgG Next Generation (BT595) - Primary Immunodeficiency Disease
Phase 3CompletedBiotest812016-10-042023-07-20
Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency
GC5107 - Immunologic Deficiency Syndromes
Phase 3CompletedGreen Cross Corporation492016-10-012022-12-09
Resuscitation With Albumin 5% in Dengue Haemorrhagic Fever
Albumins, Fluid - Dengue Hemorrhagic
Phase 3UnknownUniversitas Indonesia842016-10-012019-09-03
A Study to Evaluate the Safety and Efficacy of Domperidone in Pediatric Participants With Nausea and Vomiting Due to Acute Gastroenteritis
Oral Rehydration Therapy, Domperidone, Placebo - Gastroenteritis
Phase 3TerminatedJanssen-Cilag International NV102015-12-072019-03-20
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
C1 esterase inhibitor [human] liquid, Placebo - Hereditary Angioedema (HAE)
Phase 3CompletedShire752015-11-012021-06-08
Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV
1-dose cIPV + 2-doses bOPV (Candy), 1-dose sIPV + 2-doses bOPV (Candy), 2-doses cIPV + 1-dose bOPV (Candy) - Poliomyelitis
Phase 3CompletedInstitute of Medical Biology, Chinese Academy of Medical Sciences12002015-09-152023-10-11
Efficacy of Melatonin in Patients With Severe Sepsis or Septic Shock
Melatonin - Severe Sepsis, Septic Shock
Phase 3UnknownAragon Institute of Health Sciences1102013-05-012013-05-21
Emollients in the Management of Atopic Dermatitis
glycerol, paraffin (liquid and white soft), Atopiclair®, Locatop@ - Atopic Dermatitis
Phase 3CompletedPierre Fabre Medicament3472013-02-012014-02-19
Study to Assess Longer-term Opioid Medication Effectiveness (SALOME)
Hydromorphone, Injectable, Diacetylmorphine, injectable, Hydromorphone, liquid oral - Opioid Dependence, Heroin Dependence
Phase 3CompletedUniversity of British Columbia2022011-12-012016-06-07
Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency
Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™ - Immunologic Deficiency Syndrome
Phase 3CompletedGreen Cross Corporation452011-09-012014-01-10
ENterogermina® (Bacillus Clausii) In the manaGeMent of diarrheA in Children
Bacillus Clausii, Oral rehydration therapy - Gastroenteritis
Phase 3CompletedSanofi2642007-03-012009-01-21
Trial to Compare the Safety, Tolerability, Immunogenicity and Efficacy of Three Dose Levels of a Liquid Formulation of Influenza Virus Vaccine, (CAIV-T) in Healthy Children
CAIV-T, Liquid - Healthy
Phase 3CompletedMedImmune LLC19202002-02-012006-10-03

Showing 20 of 21. Sign in to see all of them.

Conditions studied

Primary Immunodeficiency Diseases (3)  ·  Gastroenteritis (2)  ·  Immunologic Deficiency Syndromes (2)  ·  Multiple Myeloma (2)  ·  Shock, Septic (2)  ·  Agammaglobulinemia (1)  ·  Angioedemas, Hereditary (1)  ·  Atrial Fibrillation (1)  ·  Burkitt Lymphoma (1)  ·  Dengue (1)  ·  Dermatitis (1)  ·  Dermatitis, Atopic (1)  ·  Eczema (1)  ·  Epilepsy (1)  ·  Hematologic Neoplasms (1)

Sponsors

Green Cross Corporation (2)  ·  MedImmune LLC (2)  ·  Aragon Institute of Health Sciences (1)  ·  Australian and New Zealand Intensive Care Research Centre (1)  ·  Biotest (1)  ·  CSL Behring (1)  ·  ECOG-ACRIN Cancer Research Group (1)  ·  GC Biopharma Corp (1)  ·  Institute of Medical Biology, Chinese Academy of Medical Sciences (1)  ·  Janssen-Cilag International NV (1)  ·  Katarzyna Kotulska (1)  ·  National Cancer Institute (NCI) (1)  ·  Pierre Fabre Medicament (1)  ·  Sanofi (1)  ·  Shire (1)

Countries

United States (8)  ·  Canada (5)  ·  Spain (5)  ·  China (3)  ·  Germany (3)  ·  Poland (3)  ·  Belgium (2)  ·  France (2)  ·  Hungary (2)  ·  Romania (2)  ·  Russia (2)  ·  United Kingdom (2)  ·  Australia (1)  ·  Austria (1)  ·  Bosnia and Herzegovina (1)

Top investigators

Chaim Roifman, MD (1)  ·  Eugenia Oveido-Joekes, Ph.D. (1)  ·  Gergely Krivan, MD (1)  ·  Katarzyna Kotulska-Jozwiak (1)  ·  Marta Kelava, MD (1)  ·  Michael R Krausz, M.D. (1)  ·  Robert Walker, MD (1)  ·  Rosario Z. Capeding, Dr. (1)  ·  Rui Liu (1)  ·  Sandra Peake, MBBS (1)  ·  Shah Pratik (1)  ·  Shaji K Kumar (1)

Results publications

PMID 25619263, PMID 27049826, PMID 28526048, PMID 30682573, PMID 31181017, PMID 33288485, PMID 34305948, PMID 35044877, PMID 35944615, PMID 36326435, PMID 36383294, PMID 36485104, PMID 39350232, PMID 40685240, PMID 42274006

NIH funding

2015 (2), U10CA180820 (2)